| 摘要 |
The ophthalmic compositions of this invention are used for treatment of diabetic corneal lesion and/of for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I): <CHEM> wherein A and B are independently lower alkylene, X, Y, and Z are independently halogen, or a pharmacologically acceptable salt thereof. <??>In addition, the ophthalmic compositions of this invention are used for treatment of non-diabetic corneal lesion, which comprise, as an active ingredient, an aldose reductase inhibitor. <??>The ophthalmic compositions of this invention are effective for treatment of at least one disease selected among corneal lesion and deteriorated corneal esthesia. |
